- Home
- XYF vs ZURA Comparison
XYF vs ZURA Comparison
Compare XYF & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XYF | ZURA |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.6M | 252.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | XYF | ZURA |
|---|---|---|
| Price | $6.07 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 231.6K | ★ 679.9K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | ★ 9.34% | N/A |
| EPS Growth | ★ 49.84 | N/A |
| EPS | ★ 5.72 | N/A |
| Revenue | ★ $1,106,908,607.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.05 | ★ N/A |
| Revenue Growth | ★ 47.14 | N/A |
| 52 Week Low | $5.44 | $0.97 |
| 52 Week High | $20.36 | $5.75 |
Technical Indicators
Market Signals| Indicator | XYF | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 53.01 |
| Support Level | $6.01 | $4.36 |
| Resistance Level | $6.74 | $5.46 |
| Average True Range (ATR) | 0.28 | 0.60 |
| MACD | 0.16 | -0.06 |
| Stochastic Oscillator | 47.69 | 37.70 |
Price Performance
Historical ComparisonAbout XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.